HomeCompareONCS vs EPRT

ONCS vs EPRT: Dividend Comparison 2026

ONCS yields 721.50% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCS wins by $1167526.94M in total portfolio value
10 years
ONCS
ONCS
● Live price
721.50%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1167527.00M
Annual income
$917,400,379,323.42
Full ONCS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ONCS vs EPRT

📍 ONCS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCS
Annual income on $10K today (after 15% tax)
$61,327.56/yr
After 10yr DRIP, annual income (after tax)
$779,790,322,424.91/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ONCS beats the other by $779,790,311,510.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCS + EPRT for your $10,000?

ONCS: 50%EPRT: 50%
100% EPRT50/50100% ONCS
Portfolio after 10yr
$583763.53M
Annual income
$458,700,196,082.07/yr
Blended yield
78.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ONCS
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-59.8
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCS buys
0
EPRT buys
0
No recent congressional trades found for ONCS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCSEPRT
Forward yield721.50%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1167527.00M$63.4K
Annual income after 10y$917,400,379,323.42$12,840.73
Total dividends collected$1147386.89M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: ONCS vs EPRT ($10,000, DRIP)

YearONCS PortfolioONCS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$82,850$72,150.07$11,205$505.18+$71.6KONCS
2$647,307$558,657.82$12,672$682.46+$634.6KONCS
3$4,771,864$4,079,244.95$14,490$930.48+$4.76MONCS
4$33,210,240$28,104,345.93$16,786$1,282.69+$33.19MONCS
5$218,333,899$182,798,941.49$19,753$1,791.56+$218.31MONCS
6$1,356,770,606$1,123,153,334.78$23,677$2,541.64+$1356.75MONCS
7$7,974,641,684$6,522,897,135.54$29,008$3,672.99+$7974.61MONCS
8$44,364,079,088$35,831,212,485.47$36,463$5,425.08+$44364.04MONCS
9$233,763,200,588$186,293,635,964.16$47,238$8,221.57+$233763.15MONCS
10$1,167,527,003,952$917,400,379,323.42$63,385$12,840.73+$1167526.94MONCS

ONCS vs EPRT: Complete Analysis 2026

ONCSStock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Full ONCS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ONCS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCS vs SCHDONCS vs JEPIONCS vs OONCS vs KOONCS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.